{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:06Z","timestamp":1761897126863},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Carfilzomib and daratumumab are licensed in relapsed\/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We used data from dossiers prepared for the German Federal Joint Committee based on two phase III randomized trials of carfilzomib-based therapies (ASPIRE, ENDEAVOR) and two of daratumumab-based therapies (POLLUX, CASTOR) to conduct a descriptive assessment of health-related quality of life (HRQoL). HRQoL was assessed using the European Organisation for Research and Treatment of Cancer 30-item HRQoL Questionnaire, with hazard ratios calculated for carfilzomib- and daratumumab-based therapy versus comparators for time to HRQoL deterioration of\u2009\u2265\u200910 points. Analyses were also conducted on data from the EORTC 20-item myeloma-specific questionnaire, the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity scale, and the visual analog scale of the EuroQoL 5-dimension, 5-level questionnaire, where results for these instruments were available. As the designs and patient population of the four trials were similar but not identical, the analysis included only indirect, descriptive comparisons.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Compared with lenalidomide\/dexamethasone, median time to deterioration in global health status\/QoL was longer for carfilzomib-based therapy versus control, but similar for daratumumab-based therapy and control. Compared with bortezomib\/dexamethasone, time to deterioration was significantly longer for carfilzomib-based therapy versus control for global health status\/QoL and numerous functional and symptom subscales. HRQoL measurement is feasible in large RRMM populations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Descriptive assessment of HRQoL data suggests potential benefits for carfilzomib-based over daratumumab-based therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11136-019-02307-5","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T17:03:55Z","timestamp":1569344635000},"page":"69-79","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed\/refractory multiple myeloma, based on German benefit assessment data"],"prefix":"10.1007","volume":"29","author":[{"given":"Katja","family":"Weisel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Rieth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lebioda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"issue":"4","key":"2307_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A., Fonseca, R., et al. (2017). Therapy for relapsed multiple myeloma: Guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clinic Proceedings,92(4), 578\u2013598.","journal-title":"Mayo Clinic Proceedings"},{"key":"2307_CR2","unstructured":"National Cancer Institute. (2019). Surveillance, Epidemiology, and End Results Program. Cancer Stat facts: Myeloma. Retrieved May 21, 2019, from \nhttps:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html\n\n."},{"key":"2307_CR3","unstructured":"W\u00f6rmann, B., Driessen, C., Einsele, H., Goldschmidt, H., Gunsilius, E., & Kort\u00fcm, M., et al. (2018). Multiple myeloma. Retrieved May 21, 2019, from \nhttps:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiples-myelom\/@@view\/html\/index.html\n\n."},{"issue":"9","key":"2307_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., et al. (2017). Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia,31(9), 1915\u20131921.","journal-title":"Leukemia"},{"issue":"10","key":"2307_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W. J., Oriol, A., et al. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial. The lancet Oncology,18(10), 1327\u20131337.","journal-title":"The lancet Oncology"},{"issue":"3","key":"2307_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., et al. (2018). Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood,131(3), 301\u2013310.","journal-title":"Blood"},{"issue":"4","key":"2307_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren, O., & Iskander, K. (2017). Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes. Journal of Internal Medicine,281(4), 365\u2013382.","journal-title":"Journal of Internal Medicine"},{"issue":"8","key":"2307_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel, D. S., Dimopoulos, M. A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., et al. (2018). Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology,36(8), 728\u2013734.","journal-title":"Journal of Clinical Oncology"},{"key":"2307_CR9","unstructured":"World Health Organization. (2018). WHOQOL: Measuring quality of life. Retrieved May 21, 2019, from \nhttps:\/\/www.who.int\/healthinfo\/survey\/whoqol-qualityoflife\/en\/\n\n."},{"key":"2307_CR10","unstructured":"International Society for Quality of Life Research. (2018). What is health-related quality of life research? \nhttp:\/\/www.isoqol.org\/about-isoqol\/what-is-health-related-quality-of-life-research\n\n. Accessed May 21, 2019."},{"issue":"3","key":"2307_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","volume":"72","author":"N Gulbrandsen","year":"2004","unstructured":"Gulbrandsen, N., Hjermstad, M. J., & Wisloff, F. (2004). Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. European Journal of Haematology,72(3), 172\u2013180.","journal-title":"European Journal of Haematology"},{"issue":"2","key":"2307_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","volume":"83","author":"AT Johnsen","year":"2009","unstructured":"Johnsen, A. T., Tholstrup, D., Petersen, M. A., Pedersen, L., & Groenvold, M. (2009). Health related quality of life in a nationally representative sample of haematological patients. European Journal of Haematology,83(2), 139\u2013148.","journal-title":"European Journal of Haematology"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler, C., Osborne, T. R., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., et al. (2016). The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer,16, 427.","journal-title":"BMC Cancer"},{"issue":"10","key":"2307_CR14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld, P., Verelst, S. G., Lewis, P., Gray-Schopfer, V., Hutchings, A., Nixon, A., et al. (2013). Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia,27(10), 1959\u20131969.","journal-title":"Leukemia"},{"issue":"1","key":"2307_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge, M., Dhawan, R., Robinson, D., Jr., Meunier, J., Regnault, A., Esseltine, D. L., et al. (2012). Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: Results from the VISTA trial. European Journal of Haematology,89(1), 16\u201327.","journal-title":"European Journal of Haematology"},{"issue":"6","key":"2307_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge, M., Minuk, L., Eisenmann, J. C., Arnulf, B., Canepa, L., Fragasso, A., et al. (2015). Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: Lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica,100(6), 826\u2013833.","journal-title":"Haematologica"},{"issue":"8","key":"2307_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"X Leleu","year":"2018","unstructured":"Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., et al. (2018). Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. American Journal of Hematology,93(8), 985\u2013993.","journal-title":"American Journal of Hematology"},{"issue":"2","key":"2307_CR18","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2014.112557","volume":"100","author":"KW Song","year":"2015","unstructured":"Song, K. W., Dimopoulos, M. A., Weisel, K. C., Moreau, P., Palumbo, A., Belch, A., et al. (2015). Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma. Haematologica,100(2), e63\u2013e67.","journal-title":"Haematologica"},{"issue":"9","key":"2307_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","volume":"15","author":"K Weisel","year":"2015","unstructured":"Weisel, K., Dimopoulos, M., Song, K. W., Moreau, P., Palumbo, A., Belch, A., et al. (2015). Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clinical Lymphoma, Myeloma & Leukemia,15(9), 519\u2013530.","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"3","key":"2307_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","volume":"8","author":"H Maes","year":"2015","unstructured":"Maes, H., & Delforge, M. (2015). Optimizing quality of life in multiple myeloma patients: Current options, challenges and recommendations. Expert Review of Hematology,8(3), 355\u2013366.","journal-title":"Expert Review of Hematology"},{"issue":"1","key":"2307_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18553\/jmcp.2018.24.1.29","volume":"24","author":"JJ Carlson","year":"2018","unstructured":"Carlson, J. J., Guzauskas, G. F., Chapman, R. H., Synnott, P. G., Liu, S., Russo, E. T., et al. (2018). Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy,24(1), 29\u201338.","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"7","key":"2307_CR22","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018). Patient-reported outcomes in relapsed\/refractory multiple myeloma: A systematic review. Supportive Care in Cancer,26(7), 2075\u20132090.","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"2307_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hajek, R., et al. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. The lancet Oncology,17(1), 27\u201338.","journal-title":"The lancet Oncology"},{"issue":"2","key":"2307_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine,372(2), 142\u2013152.","journal-title":"New England Journal of Medicine"},{"key":"2307_CR25","unstructured":"Amgen Europe B.V. (2019). Kyprolis. Summary of product characteristics. Retrieved May 21, 2019, from \nhttps:\/\/www.medicines.org.uk\/emc\/product\/5061\n\n."},{"key":"2307_CR26","unstructured":"Amgen Inc. (2019). Kyprolis. Prescribing information. Retrieved May 21, 2019, from \nhttps:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/kyprolis\/kyprolis_pi.pdf\n\n."},{"issue":"3","key":"2307_CR27","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers, M., Tai, Y. T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C., et al. (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology,186(3), 1840\u20131848.","journal-title":"Journal of Immunology"},{"issue":"14","key":"2307_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., et al. (2016). Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine,375(14), 1319\u20131331.","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"2307_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., et al. (2016). Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine,375(8), 754\u2013766.","journal-title":"New England Journal of Medicine"},{"key":"2307_CR30","unstructured":"Janssen-Cilag International NV. (2019). Darzalex. Summary of product characteristics. Retrieved May 21, 2019, from \nhttps:\/\/www.medicines.org.uk\/emc\/product\/7250\n\n."},{"key":"2307_CR31","unstructured":"Janssen Pharmaceutical Companies. (2019). Darzalex. Prescribing information. Retrieved May 21, 2019, from \nhttp:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf\n\n."},{"key":"#cr-split#-2307_CR32.1","unstructured":"Gemeinsamer Bundesausschuss. (2018). Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V - Daratumumab (neues Anwendungsgebiet"},{"key":"#cr-split#-2307_CR32.2","unstructured":"Neubewertung eines Orphan Drugs nach \u00dcberschreitung der 50 Mio. Euro Grenze). Retrieved May 21, 2019, from  https:\/\/www.g-ba.de\/downloads\/39-261-3222\/2018-02-15_AM-RL_XII_Daratumumab_D-310_BAnz.pdf  ."},{"key":"2307_CR33","unstructured":"Gemeinsamer Bundesausschuss. (2018). Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII \u2013 Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V \u2013 Carfilzomib (Neubewertung eines Orphan\u2013Drugs nach \u00dcberschreitung der 50 Mio. Euro-Grenze). Retrieved May 21, 2019, from \nhttps:\/\/www.g-ba.de\/downloads\/39-261-3220\/2018-02-15_AM-RL-XII_Carfilzomib_D-302_BAnz.pdf\n\n."},{"key":"2307_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3324\/haematol.2016.151837","volume":"102","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A., Moreau, P., Nahi, H., Plesner, T., Goldschmidt, H., Suzuki, K., et al. (2017). Efficacy and safety of daratumumab, lenalidomide, and dexamethasone versus Rd alone in relapsed or refractory multiple myeloma: Updated analysis of pollux. Haematologica,102, 108\u2013109.","journal-title":"Haematologica"},{"issue":"Suppl 22","key":"2307_CR35","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1182\/blood.V128.22.3309.3309","volume":"128","author":"H Ludwig","year":"2016","unstructured":"Ludwig, H., Moreau, P., Dimopoulos, M. A., Mateos, M. V., Kaiser, M. F., Feng, S., et al. (2016). Health related quality of life results from the open-label, randomized, phase III ENDEAVOR trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood,128(Suppl 22), 3309.","journal-title":"Blood"},{"issue":"32","key":"2307_CR36","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart, A. K., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., et al. (2016). Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Journal of Clinical Oncology,34(32), 3921\u20133930.","journal-title":"Journal of Clinical Oncology"},{"key":"2307_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3324\/haematol.2016.146076","volume":"102","author":"K Weisel","year":"2017","unstructured":"Weisel, K., Lentzsch, S., Mateos, M. V., Hungria, V., Munder, M., Nooka, A., et al. (2017). Efficacy and safety of daratumumab, bortezomib and dexamethasone (DVD) versus bortezomib and dexamethasone (VD) in relapsed or refractory multiple myeloma (RRMM): Updated analysis of CASTOR. Haematologica,102, 168\u2013169.","journal-title":"Haematologica"},{"issue":"5","key":"2307_CR38","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jval.2013.05.004","volume":"16","author":"CL Shih","year":"2013","unstructured":"Shih, C. L., Chen, C. H., Sheu, C. F., Lang, H. C., & Hsieh, C. L. (2013). Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value in Health,16(5), 848\u2013854.","journal-title":"Value in Health"},{"issue":"4","key":"2307_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","volume":"87","author":"AK Kvam","year":"2011","unstructured":"Kvam, A. K., Fayers, P. M., & Wisloff, F. (2011). Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of Haematology,87(4), 330\u2013337.","journal-title":"European Journal of Haematology"},{"issue":"5","key":"2307_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s11136-014-0853-y","volume":"24","author":"CF Snyder","year":"2015","unstructured":"Snyder, C. F., Blackford, A. L., Sussman, J., Bainbridge, D., Howell, D., Seow, H. Y., et al. (2015). Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients\u2019 supportive care needs. Quality of Life Research,24(5), 1207\u20131216.","journal-title":"Quality of Life Research"},{"issue":"1","key":"2307_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology,29(1), 89\u201396.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2307_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology,16(1), 139\u2013144.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"2307_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.15248","volume":"181","author":"PG Richardson","year":"2018","unstructured":"Richardson, P. G., Schlossman, R. L., Roy, A. N., Panneerselvam, A., Acharyya, S., Sopala, M., et al. (2018). Patient-reported outcomes of multiple myeloma patients treated with panobinostat after\u2009\u2265\u20092 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. British Journal of Haematology,181(5), 628\u2013636.","journal-title":"British Journal of Haematology"},{"issue":"6","key":"2307_CR44","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois, D., Dhawan, R., van de Velde, H., Esseltine, D., Gupta, S., Viala, M., et al. (2006). Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma. Journal of Clinical Oncology,24(6), 976\u2013982.","journal-title":"Journal of Clinical Oncology"},{"key":"2307_CR45","unstructured":"Siegel, D., Ludwig, H., Moreau, P., Mateos, M.-V., Niesvizky, R., & Chng, W. J., et al. (2018). Association of clinical response with survival and quality of life after carfilzomib and dexamethasone (Kd56) treatment in the phase III ENDEAVOR trial. Presented at the European Hematology Association Annual Meeting, Stockholm, Sweden."},{"issue":"1","key":"2307_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1188\/12.CJON.86-89","volume":"16","author":"A Berkowitz","year":"2012","unstructured":"Berkowitz, A., & Walker, S. (2012). Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clinical Journal of Oncology Nursing,16(1), 86\u201389.","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"6","key":"2307_CR47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3324\/haematol.2015.127860","volume":"100","author":"AK Kvam","year":"2015","unstructured":"Kvam, A. K., & Waage, A. (2015). Health-related quality of life in patients with multiple myeloma\u2014does it matter? Haematologica,100(6), 704\u2013705.","journal-title":"Haematologica"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-019-02307-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T23:38:42Z","timestamp":1600817922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-019-02307-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1007\/s11136-019-02307-5","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"14 September 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Katja Weisel has received honoraria from Amgen, BMS, Celgene, Janssen, Novartis, and Takeda; research funding from Amgen, Celgene, Janssen, and Sanofi; and has acted as a consultant for Amgen, Adaptive Biotech, BMS, Celgene, Janssen, Juno, Sanofi, and Takeda. Heinz Ludwig has received research funding from Amgen and Takeda; speaker bureau honoraria from Amgen, Takeda, Janssen-Cilag, BMS, and Celgene; and advisory board honoraria from Abbvie, Takeda, and Amgen. Achim Rieth and Andrea Lebioda are employees of Amgen GmbH and hold shares and stock options. Hartmut Goldschmidt has received research support from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Takeda, and Novartis; speaker bureau honoraria from ArtTempi, BMS, Celgene, Chugai, Janssen, and Novartis; and is a member of advisory boards for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}